Table 1 Vaccine list and efficacy (as of August 2022)
Manufacturer | Vaccine | Platform | No. of Countries in Use | Efficacy* (Infection) | Efficacy* (Severe) | References | |
|---|---|---|---|---|---|---|---|
1 | Moderna | Spikevac (mRNA-1273) | RNA | 87 | 93.2% | 98.2% | [19] |
2 | Pfizer/BioNTech | Comirnaty (BNT162b2) | RNA | 146 | 91.3% | 96.7% | [11] |
3 | Janssen (Johnson & Johnson) | Ad26.COV2.S | Non Replicating Viral Vector | 111 | 52.4% | 74.6% | [29] |
4 | Oxford/AstraZeneca | Vaxzevria (ChAdOx1 nCoV-19, AZD1222) | Non Replicating Viral Vector | 141 | 74.0% | 100% | [269] |
5 | Serum Institute of India | Covishield (Oxford/AstraZeneca formulation) | Non Replicating Viral Vector | 49 | |||
6 | Bharat Biotech | Covaxin (BBV152) | Inactivated | 14 | 77.8% (symptomatic), 63.6% (asymp) | 93.4% | [47] |
7 | Beijing Institute of Biological Products/Sinopharm | Covilo (BBIBP-CorV) | Inactivated | 91 | 78.1% | 100% | [36] |
8 | Sinovac Biotech | CoronaVac (PiCoVacc) | Inactivated | 56 | 50.7% (Brazil) 65.3% (Indonesia) 83.5% (Turkey) | 100% (Brazil) | |
9 | Novavax | Nuvaxovid (NVX-CoV2373) | Protein subunit | 38 | 89.7 (UK) 90.4% (US&Mexico) | 100% | |
10 | Serum Institute of India | COVOVAX (Novavax formulation) | Protein subunit | 5 | |||
11 | CanSino Biologics | Convidecia (AD5-nCoV) | Non Replicating Viral Vector | 10 | 57.5% | 91.7% | [33] |